TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04648358
Drug: Dexamethasone combined with bupivacaine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
Study: NCT00093990
Drug: Tipifarnib;Zarnestra; R115777
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01816282
Drug: Evicel
Normalized name: Evicel
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
Study: NCT03098953
Drug: Loteprednol Etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one drop per eye for each eye
Study: NCT00998946
Drug: Pralatrexate
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pralatrexate injection administered as intravenous (IV) push
Study: NCT02483975
Drug: FF
Normalized name: MFF
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Study: NCT01144286
Drug: arasertaconazole nitrate
Normalized name: Arasertaconazole
DrugBank: Arasertaconazole (DB19151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arasertaconazole nitrate pessary, placebo pessary
Study: NCT02483975
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast will be provided as 4 mg and 5 mg chewable tablets.
Study: NCT02483975
Drug: Albuterol/Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol/Salbutamol will be provided as inhalation aerosol.
Study: NCT02969837
Drug: Elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15
Study: NCT02969837
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond
Study: NCT02969837
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be given on days 1-21 for all cycles.
Study: NCT02969837
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22
Study: NCT02230007
Drug: MEOPA
Normalized name: homeopathic drugs
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 sessions of reeducation using MEOPA
Study: NCT00264797
Drug: Methylphenidate (OROS-MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be scheduled for weekly medication (OROS-MPH) and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
Study: NCT00264797
Drug: Methylphenidate (OROS-MPH) - Placebo
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be scheduled for weekly medication and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH placebo for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
Study: NCT04654676
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin added on to stable doses of pre-mixed insulin with or without metformin
Study: NCT01651377
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
Study: NCT03801252
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous drugs used as prophylactic antibiotics
Study: NCT00002946
Drug: penclomedine
Normalized name: Penclomedine
DrugBank: Penclomedine (DB12987)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00270790
Drug: Amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine will be given at dose of 500 mg IV within one hour before radiation
Study: NCT00270790
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
Study: NCT00270790
Drug: Taxol
Normalized name: Taxol
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
Study: NCT00332007
Drug: Tonabersat
Normalized name: Tonabersat
DrugBank: Tonabersat (DB06578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: two tablets once daily
Study: NCT00899574
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease.
Study: NCT01919593
Drug: 2% chlorhexidine gluconate in 70% alcohol
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: skin preparation before venipuncture for blood culture in even month
Study: NCT01919593
Drug: 10%povidone iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: skin preparation before venipuncture for blood culture in odd month
Study: NCT01659905
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable Tablet
Study: NCT01659905
Drug: Singulair
Normalized name: Singulair
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg Chewable Tablet
Study: NCT00078494
Drug: EBV-LMP-2
Normalized name: EBV-CTL
DrugBank: Tabelecleucel (DB17072)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02682758
Drug: Xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wash-in of xenon for maintenance of anaesthesia
Study: NCT02733432
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral fluconazole (150mg) on Day 1
Study: NCT01986283
Drug: PF-00345439
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg capsule swallowed whole, taken once
Study: NCT01986283
Drug: PF-00345439
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg capsule chewed, taken once
Study: NCT01986283
Drug: oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg solution, taken once
Study: NCT00314509
Drug: Ciclesonide/Formoterol Combination
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04394117
Drug: Angiotensin Receptor Blockers
Normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin Receptor Blockers (ARBs) have been in clinical use for more than 30 years for their cardiac and renal protective effects. ARBs mechanism of action is through selective inhibition of angiotensin-II (Ang-II) by competitive antagonism of the angiotensin receptor. ARBs displace ang-II from the angiotensin I receptor and produce their protective effects by reducing the downstream effects of ang-II induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic response The virus causing COVID-19, SARS-CoV-2, binds to the extracellular portion of Angiotensin-Converting-Enzyme-2 (ACE2) expressed on type II alveolar cells in the lungs which is followed by internalization of ACE2 before downregulating membrane ACE2 expression. Both these components appear to require angiotensin receptor Type 1 (AT1R), and ARBs, which block the actions of AT1R, would reduce the severity of COVID-19 and reduce the duration of symptoms
Study: NCT01724918
Drug: Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03097120
Drug: 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily
Study: NCT03797729
Drug: Tirofiban
Normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive Tirofiban(0.05mg/ml) intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
Study: NCT04234568
Drug: Lutetium Lu 177 Dotatate
Normalized name: Lutetium Lu 177 dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04234568
Drug: Triapine
Normalized name: Triapine
DrugBank: Triapine (DB11940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04004442
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab: 800 mg IV every two weeks (on days 1 and 15 of a 28-day cycle)
Study: NCT04004442
Drug: AVB-S6-500
Normalized name: AVB-S6-500
DrugBank: Batiraxcept (DB17522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVB-S6-500: 10mg/kg IV every 2 weeks (on days 1 and 15 of a 28-day cycle) Potential dose reduction: AVB-S6-500: 5mg/kg IV weekly (on days 1, 8, 15 and 22 of a 28-day cycle)
Study: NCT01743950
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg/kg every 2weeks.
Study: NCT04615273
Drug: Lonapegsomatropin
Normalized name: Lonapegsomatropin
DrugBank: Lonapegsomatropin (DB16220)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Due to the different human growth hormone (hGH) dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
Study: NCT04615273
Drug: Somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
Study: NCT02402348
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02745522
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00755196
Drug: Ointment vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment vehicle, twice daily for 12 weeks
Study: NCT03229057
Drug: OCP + Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
Study: NCT03229057
Drug: Metformin + Placebo
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
Study: NCT02720510
Drug: Revlimid
Normalized name: Revlimid
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Revlimid was used with dexamethasone to treat patients with multiple myeloma
Study: NCT02720510
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma
Study: NCT02720510
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone was a steroid used to treat patients with multiple myeloma.
Study: NCT02720510
Drug: Farydak
Normalized name: Farydak
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
Study: NCT03677141
Drug: Mosunetuzumab
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous (IV) mosunetuzumab.
Study: NCT01604850
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Study: NCT03677141
Drug: Polatuzumab Vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive polatuzumab vedotin via IV.
Study: NCT03677141
Drug: Rituxumab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive rituxumab via IV.
Study: NCT01511198
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously once daily
Study: NCT03677141
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive vincristine via IV.
Study: NCT03677141
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive oral prednisone.
Study: NCT01511198
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg twice daily, administered orally
Study: NCT03677141
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive tocilizumab via IV.
Study: NCT00019097
Drug: keyhole limpet hemocyanin
Normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00019097
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00019097
Drug: sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000308
Drug: Dextroamphetamine
Normalized name: Dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
Study: NCT00000308
Drug: D-amphetamine
Normalized name: d-amphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
Study: NCT00189982
Drug: Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
Normalized name: ANTIHEMOPHILIC FACTOR,HUMAN
DrugBank: Antihemophilic factor human (DB13192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator). Once the treatment regimen was established, the regimen was to be maintained for the duration of the study, unless clinical reasons necessitated a change.~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.
Study: NCT01397890
Drug: Budesonide/formoterol (Symbicort® Turbuhaler®)
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
Study: NCT01397890
Drug: Tiotropium (SpirivaTM)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
Study: NCT00462618
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002579
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01352520
Drug: SGN-35
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
Study: NCT01153984
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150 mg oral doses will be administered daily.
Study: NCT03821883
Drug: Aspirin Tablet
Normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100mg qd
Study: NCT02567409
Drug: Berzosertib
Normalized name: Berzosertib
DrugBank: Berzosertib (DB11794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02567409
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02567409
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04572295
Drug: E7090
Normalized name: Elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7090 oral tablet.
Study: NCT04572295
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant intramuscular injection.
Study: NCT04572295
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane oral tablet.
Study: NCT04446351
Drug: GSK6097608
Normalized name: Immunoglobulin G1, anti-(human CD96 antigen) (human monoclonal GSK6097608 γ1-chain), disulfide with human monoclonal GSK6097608 κ-chain, dimer
DrugBank: Nelistotug (DB19334)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK6097608 will be administered as an IV infusion.
Study: NCT04446351
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab will be administered as an IV infusion.
Study: NCT04446351
Drug: Cobolimab
Normalized name: Cobolimab
DrugBank: Cobolimab (DB16372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobolimab will be administered as an IV infusion.
Study: NCT04446351
Drug: Belrestotug
Normalized name: Belrestotug
DrugBank: Belrestotug (DB19066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belrestotug will be administered as an IV infusion.
Study: NCT02974647
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01051232
Drug: Active
Normalized name: Active
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
Study: NCT01051232
Drug: Active
Normalized name: Active
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
Study: NCT01051232
Drug: Active
Normalized name: Active
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.